TMCnet - World's Largest Communications and Technology Community



Law Offices of Howard G. Smith Announces Investigation on Behalf of Investors of Aegerion Pharmaceuticals, Inc.
[January 09, 2014]

Law Offices of Howard G. Smith Announces Investigation on Behalf of Investors of Aegerion Pharmaceuticals, Inc.

BENSALEM, Pa. --(Business Wire)--

Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (NASDAQ:AEGR) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by Aegerion concerning the Company's business, operations and financial prospects. Please contact Law Offices of Howard G. Smith to discuss this matter or other potential claims if you are a long-term shareholder of Aegerion.

Aegerion is a biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases in the United States. The Company's lead product, Juxtapid (lomitapide) capsules, is an adjunct to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia - a rare genetic dsease that impairs the function of the receptor responsible for removing low-density lipoprotein cholesterol from the blood.

The investigation is related to the Company's January 9, 2014, disclosure that Aegerion has received a subpoena from the United States Department of Justice, represented by the U.S. Attorney's Office in Boston, Massachusetts, requesting documents regarding the Company's marketing and sale of Juxtapid in the United States. According to an article published that same day by Bloomberg (News - Alert) News, the Company's chief executive officer received a warning letter from the Food and Drug Administration in November, stating that the CEO's comments in an interview on CNBC "provide evidence that Juxtapid is intended for new uses, for which it lacks approval and for which its labeling does not provide adequate directions for use."

If you purchased Aegerion stock and still hold those shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to, or visit our website at

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy